You can draw your own conclusions as to why the posters who
You can draw your own conclusions as to why the posters who admit they are not IPIX shareholders continue to post on the other board on a 3 cent stock? It has been a difficult time for actual IPIX shareholders since the B-CV19 trial failed to meet endpoint goals. I personally and incorrectly believed that Brilacidin would meet endpoints in the CV19 trial based on previous success in efficacy and safety in other trials and the extensive testing at the Regional Biocontainment Lab. The sad truth is that IPIX share price would be in the dollars per share today vs 3 cents if this trial had been a success. There are endless people and organizations that some want to point fingers at for this failure including the FDA, Fauci, Leo, the Russians, CRO’s etc. Everyone has their own list and ranking of the culprits.
I personally only have 2 entities to blame.
#1 The Criminal Hedge Fund Short Selling Cabal.
IMO this NSS attack has been in place for 7 years or so. Leo’s biggest fault was not recognizing this sooner and raising cash while SP was over $2 per share. IMO if the hedge funds had not illegally targeted IPIX, Leo would have been able to raise sufficient cash without significant dilution. If capital had not been so extremely expensive due to artificial and illegal SP compression, Brilacidin would have been an approved drug long before the world had ever heard of Covid. The only glimmer of good news is that the criminals continue to have massive NSS exposure. If they had covered their naked position on IPIX, the paid multi identities would be long gone. Their plan is to never have to cover their position by putting their targeted companies out of business. To force a NSS cover, Leo would need to execute significant milestones (major license agreement, merge or buyout). IPIX investors that have hung on to some or all of their position can only hope Leo can put some type of deal together. The verbiage in the recent 10-Q indicates that IPIX science will not advance until some type of structured deal is in place. Until that time IMO Leo will continue to minimize expenses.
#2 Myself.
No one put a gun to my head to buy IPIX shares. I did my own due diligence and weighed what I felt were the risks vs the rewards and incorrectly determined that IPIX was a potentially lucrative investment. Up to this point in time I have been wrong in my assessment. Time will tell if IPIX will become a profitable investment but all prior guestimations of potential SP went out the window with the failed trial. Every SP guestimation was based on the assumption that Brilacidin would become a dominant treatment for CV19 which is highly unlikely at this point in time. That assumption has not come to fruition.
There are IPIX investors that I personally know who have completely sold their entire position and moved on, many of who have sold 20% to 50% of their position. There are also a few investors that continue to add to their positions in this 3 cent range to lower their average cost. IMO any investor who intended to sell some or all of their IPIX shares has already done so.
So what now? Those of us who have held a significant percentage of our IPIX holdings can only wait while IPIX appears to be in a holding pattern. Either Leo is successful in putting together some type of deal or structure whereas shareholders could still potentially make a profit or if not IPIX SP will continue to drift lower. I still believe in the science and I am hopeful that Leo can pull something off. As we wait do not forget who is responsible for the position IPIX is in.
11
14
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...
Continue Reading
Workday Secures Leadership Position In a wild ride that's left investors with whiplash in recent years, Workday (NASDAQ: WDAY) has firmly planted its flag at the top tier of the 2026 Gartner® Magic Quadrant™ for Cloud ERP Finance. This announcement out of Pleasanton, California, resonates like a victory bell for the company's finance management solutions—a mix of AI,...
Continue Reading
The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...
Continue Reading
What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...
Continue Reading
Unveiling the LB-30 Cyclotron at EANM 2026 Life in nuclear medicine never stands still, and once again, Longevous Beamtech (LBT) is stirring the pot with its brand-new LB-30 series medical cyclotron. They rolled out this high-powered beast at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. Leaning into the 30 MeV energy...
Continue Reading
Greasing the Wheels of Miami's Wellness Scene If you're living under a rock, you might not have noticed, but CorePower Yoga is making some serious moves in Miami. We're talking about two new studios opening their doors: one in Midtown Miami, already rolling out the mats as of October 19, and another flagship joint soon to hit Coral Gables. Clearly, they see the demand for...
Continue Reading
Ryan Stills: A Comeback Story for the Ages Ryan Stills isn't just lifting weights; he's lifting the entire perception of what's possible after a heavy surgical setback. We're talking about a guy who stared down a hemi-shoulder replacement—a career ender for many—and came out the other side with a whole new set of gold medals. Two years ago, some might have written him...
Continue Reading
From Bonds to Ballgames: Hinojosa's Impact Listen up, because this one’s more than just another accolade on a shelf. Noé Hinojosa Jr., a big gun over at TRB Securities, is getting the 2026 Hispanic Business Salute Award, and it's a doozy. Awarded by all the big wigs—UPS, NBC 5, Telemundo 39, and the Dallas Cowboys—this isn't a small pat on the back. It's a full-on...
Continue Reading
Senté's Science-Driven Approach in Skincare Alright, cutting through the skincare noise, Senté Labs has pulled off something impressive—not just another jar of promises but actual, peer-reviewed science backing their Defense C Serum. Published in the Journal of Cosmetic Dermatology, this study isn't just talk about ingredients; it's a show of real results. This isn't...
Continue Reading
The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...
Continue Reading
Top 5 Most Recently Viewed Articles
Wuxi Xishan Golden Autumn Investment Symposium Highlights WUXI, China – The recent Wuxi Xishan Golden Autumn Investment and Cooperation Symposium emerged as a significant event focusing on investment opportunities. The symposium took place with the theme "Infinite Opportunities with Xishan" and saw participation from over 200 esteemed business leaders, academic experts,...
Continue Reading
Nexxen's Strategic Appointment in Data Leadership Nexxen, an innovative advertising technology platform known for its advanced TV and data proficiency, has made an impactful appointment. They have recruited Eric Solomon as their new Senior Vice President of Product – Data. This decision highlights their dedication to driving growth through data and analytics. Role of...
Continue Reading
Investors of Brunello Cucinelli S.p.A. Urged to Take Action Brunello Cucinelli S.p.A. (OTC: BCUCY) shareholders have an important opportunity to scrutinize the recent allegations made against the company regarding potentially misleading business claims. With rising concerns about the accuracy of public statements, this situation calls for a proactive approach from...
Continue Reading
MTY Food Group Sees Growth in Q3 2025 MTY Food Group Inc. (“MTY” or the “Company”) (TSX: MTY) has reported its financial performance for the third quarter of fiscal 2025. The Company continues to thrive amidst the ongoing challenges in the macroeconomic landscape. Despite fluctuations, MTY's strategic initiatives are paving the way for stability and sustained...
Continue Reading
Blade Air Mobility Announces Earnings Release Date Blade Air Mobility, Inc. (Nasdaq: BLDE), a key player in the air mobility sector, is set to unveil its financial performance for the first quarter ending March 31, 2025. The announcement will be made on a Monday, specifically May 12, 2025, before the market opens, marking an important event for investors and stakeholders...
Continue Reading